- Written by Niharika Midha, MSc, GlobalData's Research Analyst covering Diagnostic Imaging.
The much-awaited results from the OSLO breast cancer screening trial, which looked at the accuracy of tomosynthesis in conjunction with mammography compared with mammography alone, finally came to an end early this month. The results of the trial confirm that the great promise of this new technology, pioneered by Hologic, holds. This coincided with reports that several hospitals in the US have already embarked on upgrading to tomosynthesis at lightning speed.
Hologic was the first company to get approval for its tomosynthesis device, in 2011, and since then has marketed the product worldwide. Hologic showcased this technology, along with other innovations in the space, at the recent 38th Arab Health Congress in Dubai.
The OSLO trial was the first large-scale peer-reviewed study, and its purpose was to compare conventional 2D mammography, 2D mammography combined with computer-aided detection (CAD), 2D mammography with tomosynthesis, and synthetic 2D mammogram combined with tomosynthesis. The first trials results, released on January 9, discuss the comparison between 2D mammography and 2D mammography combined with tomosynthesis.